Trial Profile

A first in-human Phase 1 single-ascending dose (SAD) clinical trial evaluating LP659 in Healthy Volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LP 659 (Primary)
Indications Neurological disorders
Focus Adverse reactions; First in man
Sponsors Longboard Pharmaceuticals

Most Recent Events

29 Jul 2024 According to a Longboard Pharmaceuticals media release, company to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers.
29 Jul 2024 According to a Longboard Pharmaceuticals media release, the company will host a conference call and webcast, plans to release second quarter 2024 financial results and provide a corporate update, including topline from this study.
12 Mar 2024 According to a Longboard Pharmaceuticals media release, phase 1 SAD topline data expected in Q2 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com